Biogen has entered into an agreement to acquire Nightstar Therapeutics for $800 million. Nightstar is a clinical-stage gene therapy company based in London, UK, which is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders.   “Ophthalmology is an emerging growth area for Biogen, and we are excited about the opportunity to work with the talented employees at Nightstar to advance potentially transformative gene therapy programs for rare retinal diseases,” said Michel ...